Catalyst Biosciences, Inc.

158 articles with Catalyst Biosciences, Inc.

• 

  Clinical Catch-Up: February 3-7, 2020

  2/10/2020

  Although it was a relatively slow week for clinical trial updates, there were still a number of announcements. Here’s a look.

• Catalyst Biosciences Presents Positive Data from its Phase 2b Trial of Subcutaneous Dalcinonacog Alfa (DalcA) and Marzeptacog alfa (activated) (MarzAA) Programs at the 13th Annual EAHAD Congress

  2/7/2020

  Enrollment in the DalcA trial is complete; results demonstrate DalcA provides Factor IX (FIX) activity exceeding the efficacy endpoint with no anti-drug antibodies

• Catalyst Biosciences Announces Oral and Poster Presentations at the 13th Annual EAHAD Congress

  1/27/2020

  Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced one oral and three poster presentations at the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) being held in The Hague, Netherlands on February 5 - 7, 2020.

• Catalyst Biosciences Announces Addition of Geoffrey Shiu Fei Ling, M.D. and Sharon Tetlow to Board of Directors

  1/17/2020

  Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders, today announced the appointment of Geoffrey Shiu Fei Ling, M.D. and Sharon Tetlow to the Company’s Board of Directors, effective January 15, 2020. 

• Catalyst Biosciences Announces Global License and Collaboration Agreement to Develop Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration

  12/19/2019

  Catalyst to receive $15 million upfront and is eligible to receive an additional $340 million in milestones and tiered royalties up to low double digits

• Catalyst Biosciences Presents Two Posters on MarzAA at the 61st Annual American Society of Hematology Conference

  12/9/2019

  Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders, today announced two poster presentations on Marzeptacog alfa (activated) – MarzAA, the Company’s subcutaneously administered next-generation engineered coagulation Factor VIIa (FVIIa), at the 61st Annual American Society of Hematology (ASH) meeting held December 7-10, 2019 in Orlando, Florida.

• Catalyst Biosciences to Present at the Stifel Healthcare Conference

  11/12/2019

  Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences, will present a corporate overview at the Stifel 2019 Healthcare Conference at 9:10 a.m. ET on Tuesday, November 19, 2019, in New York.

• Catalyst Biosciences Reports Third Quarter 2019 Operating & Financial Results and Provides a Corporate Update

  11/7/2019

  Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the third quarter ended September 30, 2019 and provided a corporate update.

• Catalyst Biosciences Announces Poster Presentations at the 61st Annual American Society of Hematology Conference

  11/6/2019

  Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company developing novel medicines to address hematology indications, today announced two poster presentations on Marzeptacog alfa (activated) – MarzAA, the Company’s  subcutaneously administered next-generation engineered coagulation Factor VIIa (FVIIa), at the upcoming 61st Annual American Society of Hematology (ASH) meeting being held December 7-10, 2019 in Orlando, Florida.

• 

  Clinical Catch-Up for September 31-October 4

  10/7/2019

  It was another busy week for clinical trials. Here’s a look.

• 22NW: Catalyst Biosciences Needs Change Now

  9/27/2019

  22NW, LP is one of the largest shareholders of Catalyst Biosciences, Inc ​with ownership of approximately 6% of the Company's outstanding shares.

• Catalyst Biosciences Meets the Primary Endpoint of Reduction in Annualized Bleeding Rate in the Phase 2 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Patients with Hemophilia A or B with Inhibitors

  7/8/2019

  Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the Phase 2 trial of its subcutaneous (SQ) Factor VIIa (FVIIa) variant marzeptacog alfa (activated) (MarzAA) for prophylaxis met the primary endpoint of significantly reducing the annualized bleed rate (ABR) in patients with hemophilia A or B with inhibitors.

• Catalyst Biosciences Announces Oral and Poster Presentations at the International Society on Thrombosis and Haemostasis

  7/1/2019

  Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced one oral and three poster presentations at the upcoming International Society for Thrombosis and Hemostasis(ISTH) meeting being held in Melbourne, Australia from July 6-10, 2019.

• Catalyst Biosciences to Present at the Jefferies 2019 Global Healthcare Conference

  5/28/2019

  Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences, will present a corporate overview at the Jefferies 2019 Global Healthcare Conference at 2:30 p.m. EDT on Tuesday, June 4, 2019 in New York.

• Catalyst Biosciences Reports First Quarter 2019 Operating & Financial Results and Provides a Corporate Update

  5/2/2019

  Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2019 and provided a corporate update.

• Catalyst Biosciences & Mosaic Biosciences Present Preclinical Data on Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration

  4/29/2019

  Catalyst Biosciences, Inc.(NASDAQ: CBIO), and Mosaic Biosciences today announced the presentation of new data on pegylated CB 2782 (CB 2782-PEG), Catalyst’s preclinical anti-C3 candidate being developed for the treatment of geographic atrophy (GA) associated dry age-related macular degeneration (dry AMD) at the 2019 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), being held in Vancouver, British Columbia, from April 28 - May 2, 2019.

• Catalyst Biosciences to Present at The Needham & Company 18th Annual Healthcare Conference

  4/3/2019

   Catalyst Biosciences, Inc., Inc. (NASDAQ:CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer, will present a corporate overview at the Needham & Company 18th Annual Healthcare Conference at 12:50 p.m. EDT on Tuesday, April 9, 2019 at the Westin Grand Central Hotel in New York.

• Catalyst Biosciences Initiates a Phase 2b Trial of Dalcinonacog Alfa for the Treatment of Hemophilia B

  4/2/2019

  Catalyst Biosciences, Inc. (Nasdaq:CBIO), today announced the initiation of enrollment in a Phase 2b study of dalcinonacog alfa (DalcA), a next-generation subcutaneously (SQ) administered Factor IX (FIX) therapy being developed for the treatment of hemophilia B.

• Catalyst Biosciences Receives Orphan Designation from the European Commission for Marzeptacog Alfa (Activated)

  4/1/2019

  Catalyst Biosciences, Inc. (Nasdaq: CBIO) today announced that the European Commission has awarded orphan designation of its Factor VIIa (FVIIa) variant marzeptacog alfa (activated) (MarzAA) for the treatment of haemophilia B (with or without inhibitors).

• Catalyst Biosciences Reports Fourth Quarter and Full-Year 2018 Operating & Financial Results and Provides a Corporate Update

  3/7/2019

  Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced its operating and financial results for the fourth quarter and full-year ending December 31, 2018 and provided a corporate update.